# Gemox as First and Second Line Therapy in Unknown Primary Cancer

> **NCT00353145** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Unknown Primary Neoplasms

## Interventions

- **DRUG:** Gemcitabine (Gemox)
- **DRUG:** Oxaliplatin
- **BEHAVIORAL:** Questionnaire

## Key facts

- **NCT ID:** NCT00353145
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2007-03
- **Final completion:** 2010-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2012-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353145, "Gemox as First and Second Line Therapy in Unknown Primary Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00353145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*